Guía de Práctica Clínica de Asma Grave, ALAT 2024
Barra lateral del artículo
Contenido principal del artículo
Resumen
El asma grave representa un serio problema de salud en América Latina debido al subdiagnóstico, al bajo nivel de educación sobre su manejo y a las dificultades en el acceso y tratamiento, lo que impacta significativamente en la morbimortalidad de los pacientes. En el año 2020, nuestro grupo elaboró la GUÍA de Asma Grave de la ALAT. Considerando la necesidad de actualizar y desarrollar nuevas recomendaciones, presentamos este nuevo documento, Guía ALAT 2024, donde las recomendaciones se han basado en la mejor evidencia disponible y han sido consensuadas por un grupo de expertos de las sociedades médicas latinoamericanas miembros de la ALAT. Se utilizó el panel Delphi modificado para lograr un nivel de consenso adecuado para cada una de las recomendaciones. Se incluyeron seis nuevas preguntas como el papel de la triple terapia inhalada en la definición del asma grave, los conceptos de remisión del asma y fracaso del tratamiento, la identificación de factores de riesgo de exacerbaciones, el rol de fármacos biológicos en el tratamiento del asma grave dependiente de corticoides en adultos, y la eficacia y seguridad de un anticuerpo anti-TSLP (tezepelumab). Una guía específica para el manejo del asma grave es esencial para mejorar el diagnóstico, estandarizar los tratamientos, reducir las desigualdades en la atención y fortalecer los sistemas de salud haciendo un uso más eficiente de los recursos disponibles.
Descargas
Detalles del artículo
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Citas
Cooper PJ, Figueiredo CA, Rodriguez A et al. Understanding and controlling asthma in Latin America: A review of recent research informed by the SCAALA programme. Clin Transl Allergy 2023;13(3):e12232. Doi: 10.1002/clt2.12232.
Forno E, Brandenburg DD, Castro-Rodriguez JA et al. Asthma in the Americas: An Update: A Joint Perspective from the Brazilian Thoracic Society, Canadian Thoracic Society, Latin American Thoracic Society, and American Thoracic Society. Ann Am Thorac Soc 2022;19(4):525– 35. Doi: 10.1513/AnnalsATS.202109-1068CME.
Ocampo J, Gaviria R, Sánchez J. Prevalence of asthma in Latin America. Critical look at ISAAC and other studies. Rev Alerg Mex 2017;64(2):188.
Neffen H, Chahuàn M, Hernández DD et al. Key factors associated with uncontrolled asthma–the Asthma Control in Latin America Study. J Asthma 2019;0(0):1–10. Doi: 10.1080/02770903.2018.1553050.
Solé D, Aranda CS, Wandalsen GF. Asthma: epidemiology of disease control in Latin America – short review. Asthma Res Pract 2017;3(1):4–9. Doi: 10.1186/s40733-017-0032-3.
Nathan RA, Thompson PJ, Price D et al. Taking Aim at Asthma Around the World: Global Results of the Asthma Insight and Management Survey in the Asia-Pacific Region, Latin America, Europe, Canada, and the United States. J Allergy Clin Immunol Pract 2015;3(5):734-742.e5.
Asociación Latinoamericana de Tórax. Guía de Práctica Clínica Latinoamericana de Asma Grave. Respirar. 2020;12:1–76.
García G, Bergna M, Vásquez JC et al. Severe asthma: adding new evidence – Latin American Thoracic Society. ERJ Open Res 2021;7(1):00318–2020. Doi: 10.1183/23120541.00318-2020.
Bate L, Hutchinson A, Underhill J, Maskrey N. How clinical decisions are made. Br J Clin Pharmacol 2012;74(4):614–20. Doi: 10.1111/j.1365-2125.2012.04366.x.
Montaño-Velázquez BB, Figueroa-Morales MA. Fundamentos de la Medicina Basada en Evidencias (MBE). Documento de la serie MBE , 1 de 3. Gac Mex Oncol 2014;13(5):274–7.
González-Garay AG, Mayorga-Butrón JL, Ochoa-Carrillo FJ. Revisiones sistemáticas de la literatura, la piedra angular de la medicina basada en evidencia. Documento de la serie Medicina basada en evidencia, 2 de 3. Gac Mex Oncol 2015;14(2):103–6.
Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: Developing guidelines. Bmj 1999;318(7183):593–6. Doi: 10.1136/bmj.318.7183.593.
Shekelle P, Woolf S, Grimshaw JM, Schünemann HJ, Eccles MP. Developing clinical practice guidelines: reviewing, reporting, and publishing guidelines; updating guidelines; and the emerging issues of enhancing guideline implementability and accounting for comorbid conditions in guideline development. Implement Sci 2012;7(1):1–7.
Mayorga J, Velasco L, Ochoa F. Guías de Práctica Clínica Basadas en Evidencia, cerrando la brecha entre el conocimiento científico y la toma de decisiones clínicas. Documento de la serie MBE, 3 de 3. Gac Mex Oncol 2015;6(6):329–34.
Institute of Medicine. Clinical Practice Guidelines We Can Trust Developing Trustworthy Guidelines Setting Standards for Trustworthy Guidelines. Standards. 2011. [Internet]. [Consultado 20 sept 2024]. Disponible en: www.iom.edu/cpgstandards
Scottish Intercollegiate Guidelines Network. A Guideline Developer’s Handbook. Edinburgh, Scotland: Scottish Intercollegiate Guidelines Network. 2015. [Internet]. [Consultado 20 sept 2024 ]. Disponible en: http://www.sign.ac.uk/assets/sign50_2015.pdf
Brouwers MC, Kerkvliet K, Spithof K. The AGREE reporting checklist: A tool to improve reporting of clinical practice guidelines. BMJ 2016;352:i1152. Doi: 10.1136/bmj.i1152.
Shea BJ, Reeves BC, Wells G et al. AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 2017;358:j4008. Doi: 10.1136/bmj.j4008.
Tao H, Yang L, Ping A et al. Interpretation of AMSTAR 2: A critical appraisal tool for systematic reviews that include randomized or non-randomized studies of healthcare interventions. Chinese J Evidence-Based Med 2018;18(1):101–8.
Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. Int J Surg 2014;12(12):1495–9.
Bossuyt PM, Reitsma JB, Bruns DE et al. STARD 2015: An updated list of essential items for reporting diagnostic accuracy studies. Clin Chem 2015;61(12):1446–52. Doi: 10.1373/clinchem.2015.246280.
Jović F, Jović A, Rajković V. A contribution to the investigation of algebraic model structures in qualitative space. MIPRO 2006 - 29th Int Conv Proc Comput Tech Syst Intell Syst 2006;3(2):90–5.
Whittle JG, Grant AA, Sarll DW, Worthington HV. The Delphi technique: its use in dental health services research assessed in a study to improve care for elderly mentally ill patients. Community Dent Health 1987;4(3):205–14.
Khodyakov D, Grant S, Kroger J, Baumanrand M. RAND Methodological Guidance for Conducting and Critically Appraising Delphi Panels. Rand 2023. [Internet]. [Consultado 20 sept 2024 ]. Disponible en: delphi process.pdf.
Brouwers MC, Vukmirovic M, Spithoff K, Makarski J. Understanding optimal approaches to patient and caregiver engagement in the development of cancer practice guidelines: A mixed methods study. BMC Health Serv Res 2017;17(1):186. Doi: 10.1186/s12913-017-2107-5.
Von Bülow A, Backer V, Bodtger U et al. Differentiation of adult severe asthma from difficult-to-treat asthma – Outcomes of a systematic assessment protocol. Respir Med 2018;145:41–7. Doi: 10.1016/j.rmed.2018.10.020.
Shiffman RN. Recognizing Trustworthy Guidelines: The New IOM Standards. Scottish Intercollegiate Guidelines Network (SIGN). A guideline developer’s handbook. Edinburgh: SIGN; 2019. (SIGN publication no. 50). [Internet]. [Consultado 20 sept 2024 ]. Disponible en: http://www.sign.ac.uk.
NICE. Developing NICE guidelines: the manual. 2014. [Internet]. [Consultado 20 sept 2024 ]. Disponible en: https://www.nice.org.uk/process/pmg20.
Mayorga J, Velasco L, Ochoa F. Guías de Práctica Clínica Basadas en Evidencia, cerrando la brecha entre el conocimiento científico y la toma de decisiones clínicas. Documento de la serie MBE, 3 de 3. Gaceta Mexicana de Oncologia 2015;6(6):329– 34.
Muiser S, Gosens R, van den Berge M, Kerstjens HAM. Understanding the role of long-acting muscarinic antagonists in asthma treatment. Ann Allergy Asthma Immunol 2022;128(4):352–60. Doi: 10.1016/j.anai.2021.12.020.
Singh D, Virchow JC, Canonica GW et al. Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER. Respir Res 2020;21(1):285. Doi: 10.1186/s12931-020-01558-y.
Lee LA, Bailes Z, Barnes N et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med 2021;9(1):69–84. Doi: 10.1016/S2213-2600(20)30389-1.
Oba Y Maduke T, Anwer S, Patel T, Dias S. Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying doses of inhaled corticosteroids in adolescents and adults with asthma: a systematic review and network meta-analysis. Cochrane Database Syst Rev 2022;12(12):CD013799. Doi: 101002/14651858CD013799.pub2.
Plaza Moral V, Alobid I, Álvarez Rodríguez C et al. Guía Española para el manejo del asma. GEMA 5.4. [Internet]. [Consultado 20 sept 2024 ]. Disponible en: www.gemasma.com
Menzies-Gow A, Hoyte FL, Price DB et al. Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab. Adv Ther 2022;39(5):2065–84.
Menzies-Gow A, Bafadhel M, Busse WW et al. An expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol 2020;145(3):757–65. Doi: 10.1016/j.jaci.2019.12.006.
Thomas D, McDonald VM, Pavord ID, Gibson PG. Asthma remission: what is it and how can it be achieved? Eur Resp J 2022;60(5):2102583. Doi: 10.1183/13993003.02583-2021.
Canonica GW, Blasi F, Carpagnano GE et al. Severe Asthma Network Italy Definition of Clinical Remission in Severe Asthma: A Delphi Consensus. J Allergy Clin Immunol Pract 2023;11(12):3629–37. Doi: 10.1016/j.jaip.2023.07.041.
Álvarez-Gutiérrez F, Casas-Maldonado F, Soto-Campos G et al. and the REMAS GROUP Spanish Consensus on Remission in Asthma (REMAS). Arch Bronconeumol 2024;60(8):503-509. Doi: 10.1016/j.arbres.2024.04.002.
Agache I, Akdis CA, Akdis M et al. EAACI Biologicals Guidelines—Recommendations for severe asthma. Allergy 2021;76(1):14–44.
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2023 (GINA, 2023). [Internet]. [Consultado 20 sept 2024 ]. Disponible en: www.ginasthma.org
Mattei L, Suehs CM, Alagha K et al. Anti- interleukin 5 therapies failure criteria in severe asthma: a Delphi-consensus study. Ther Adv Respir Dis 2021;15:175346662110497.
Akaba T, Kondo M, Kobayashi F et al. Characteristics of patients with severe asthma who experienced treatment failure with omalizumab. Pulm Pharmacol Ther 2021;68:102032.
Eger K, Kroes JA, ten Brinke A, Bel EH. Long-Term Therapy Response to Anti–IL- 5 Biologics in Severe Asthma—A Real-Life Evaluation. J Allergy Clin Immunol Pract 2021;9(3):1194–1200. Doi: 10.1016/j.jaip.2020.10.010.
Khaleva E, Rattu A, Brightling C et al. Definitions of non-response and response to biological therapy for severe asthma: a systematic review. ERJ Open Res 2023;9(3):00444–2022. Doi: 10.1183/23120541.00444-2022.
Annesi‐Maesano I, Cecchi L, Biagioni B et al. Is exposure to pollen a risk factor for moderate and severe asthma exacerbations? Allergy 2023;78(8):2121-2147. Doi: 10.1111/all.15724.
Yang F, Busby J, Heaney LG et al. Factors Associated with Frequent Exacerbations in the UK Severe Asthma Registry. J Allergy Clin Immunol Pract 2021;9(7):2691-2701.e1. Doi: 10.1016/j.jaip.2020.12.062.
Miller MK, Lee JH, Miller DP, Wenzel SE. Recent asthma exacerbations: A key predictor of future exacerbations. Respir Med 2007;101(3):481–9. Doi: 10.1016/j.rmed.2006.07.005.
Nakwan N. Impact of asthma severity as risk factor to future exacerbations in patients admitted for asthma exacerbation. Multidiscip Respir Med 2021;1;16.
Couillard S, Laugerud A, Jabeen M et al. Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide. Thorax 2022;77(2):199–202. Doi: 10.1136/thoraxjnl-2021-217325.
Henriksen DP, Bodtger U, Sidenius K et al. Efficacy of omalizumab in children, adolescents, and adults with severe allergic asthma: a systematic review, meta-analysis, and call for new trials using current guidelines for assessment of severe asthma. Allergy Asthma Clin Immunol 2020;16(1):49. Doi: 10.1186/s13223-020-00442-0.
Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 2014;2014(1):CD003559. Doi: 10.1002/14651858.CD003559.pub4.
Calzetta L, Aiello M, Frizzelli A, Bertorelli G, Rogliani P, Chetta A. Oral Corticosteroids Dependence and Biologic Drugs in Severe Asthma: Myths or Facts? A Systematic Review of Real-World Evidence. Int J Mol Sci 2021;22(13):7132.
Yılmaz İ. Biologics for oral corticosteroid-dependent asthma. Allergy Asthma Proc 2020;41(3):151–7.
Phinyo P, Krikeerati T, Vichara-Anont I, Thongngarm T. Efficacy and Safety of Biologics for Oral Corticosteroid–Dependent Asthma: A Systematic Review and Network Meta-Analysis. J Allergy Clin Immunol Pract 2024;12(2):409–20. Doi: 10.1016/j.jaip.2023.11.007.
Parnes J, Molfino NA, Colice G, Martin U, Corren J, Menzies-Gow A. Targeting TSLP in Asthma. J Asthma Allergy 2022;15:749–65. Doi: 10.2147/JAA.S275039.
Zoumot Z, Al Busaidi N, Tashkandi W et al. Tezepelumab for Patients with Severe Uncontrolled Asthma: A Systematic Review and Meta-Analysis. J Asthma Allergy 2022;15:1665–79. Doi: 10.2147/JAA.S378062.
Pitre T, Jassal T, Angjeli A et al. A comparison of the effectiveness of biologic therapies for asthma. Ann Allergy Asthma Immunol 2023;130(5):595–606. Doi: 10.1016/j.anai.2022.12.018.
Menzies-Gow A, Steenkamp J, Singh S et al. Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison. J Med Econ 2022;25(1):679–90.
Plaza V, Trigueros J and GEMAFORUM task force. Use of Triple Therapy in Asthma: The GEMAFORUM V Task Force. J Investig Allergol Clin Immunol 2024;34(4):257-260. Doi: 10.18176/jiaci.0975.